Long-Acting Injectable Cabotegravir for PrEP: Understanding Results of HPTN 083 & 084 and key areas for advocacy

Join AVAC and partners for webinar on May 3 webinar, 10-11:30am EDT where you can engage with researchers who led the studies about this injectable PrEP strategy and advocates who are leading essential advocacy efforts around the introduction of CAB-LA. On the call, lead trial investigators Sinead Delany-Moretlwe from HPTN 084 and Raphy Landovitz from HPTN 083 will provide updates, and we’ll be joined by AVAC’s Emily Bass, Chiluyfa Kasanda from TALC in Zambia, Richard Lusimbo from Pan Africa ILGA, and Sibongile Maseko who is an independent consultant and women’s health advocate based in Eswatini. Register here.